Stockwatch: Is it time to give no quarter?
This article was originally published in Scrip
Executive Summary
Does quarterly reporting actually matter at all? In the weeks of the quarterly reporting season, fund managers wake up to more than 50 new emails each morning. Then they glue themselves to their computer screens and dial into conference calls. What starts as a gentle, reasonably benign trickle of information (scripintelligence.com, 18 April 2013) becomes an acute hemorrhage of mixed results announcements, research notes and news reports.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.